Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
- 1 May 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infectionAIDS, 2000
- The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudineAIDS, 2000
- A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndromeAIDS, 2000
- Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophyAIDS, 1999
- Lipodystrophy associated with nevirapine-containing antiretroviral therapiesAIDS, 1999
- Lipodystrophy in patients naive to HIV protease inhibitorsAIDS, 1999
- Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapyAIDS, 1999
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998